News | February 20, 2022
Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
In the interim, Deepak Khanna will lead Human Health International.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
